Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta‐analysis-Reference-Cited by-同舟云学术

Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta‐analysis

Published:2019-10-14 Issue:2 Volume:96 Page:
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Kuno Toshiki¹^ORCID,Takagi Hisato²^ORCID,Sugiyama Takehiro³⁴⁵,Ando Tomo⁶^ORCID,Miyashita Satoshi¹,Valentin Nelson¹,Shimada Yuichi J.⁷,Kodaira Masaki⁸,Numasawa Yohei⁸^ORCID,Kanei Yumiko⁹,Hayashida Kentaro¹⁰^ORCID,Bangalore Sripal¹¹

Affiliation:

1. Department of Medicine Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel New York New York

2. Department of Cardiovascular Surgery Shizuoka Medical Center Shizuoka Japan

3. Diabetes and Metabolism Information Center Research Institute, Center for Global Health and Medicine Tokyo Japan

4. Department of Health Services Research, Faculty of Medicine University of Tsukuba Tsukuba Japan

5. Department of Public Health/Health Policy, Graduate School of Medicine The University of Tokyo Tokyo Japan

6. Department of Cardiology Detroit Medical Center Detroit Michigan

7. Division of Cardiology, Department of Medicine Columbia University Medical Center New York New York

8. Department of Cardiology Japanese Red Cross Ashikaga Hospital Ashikaga Japan

9. Department of Cardiology Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel New York New York

10. Department of Cardiology Keio University School of Medicine Tokyo Japan

11. New York University School of Medicine New York New York

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.28498

Reference38 articles.

1. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery

2. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients

3. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

4. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study

5. NealeT. Galileo trial of rivaroxaban after TAVR stopped early for harm. Rivaroxaban‐treated patients had increased risks of all‐cause mortality thromboembolic events and bleeding vs those on antiplatelet therapy.https://www.tctmd.com/news/galileo‐trial‐rivaroxaban‐after‐tavr‐stopped‐early‐harm.TCTMD October 09. 2018.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non–Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve Replacement;JACC: Cardiovascular Interventions;2024-02

2. Catheter-Based Therapies: Current Practices and Considerations;Aortic Valve Disease - Recent Advances [Working Title];2023-11-13

3. Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation;The American Journal of Cardiology;2023-08

4. Subclinical Leaflet Thrombosis After Balloon versus Self-Expandable Transcatheter Aortic Valve Implantation;The American Journal of Cardiology;2023-04

5. Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review;Journal of Cardiovascular Development and Disease;2023-03-23